不同病理分型原发性肝癌超声特性分析及超声介入瘤内注射无水酒精疗效研究
|
摘要
目的:探讨不同病理分型原发性肝癌的超声特性以及经皮肝穿刺瘤内注射无水酒精治疗效果的差异,增强普通超声在原发性肝癌的诊断和治疗中的应用价值。
方法:(一)回顾性分析了2007年4月至10月期间在我院行手术治疗的552例原发性肝癌患者术前超声检查结果,统计肿瘤回声强弱、肿瘤位置、肿瘤边界是否清晰、肿瘤数目等超声特性,按照术后病理结果将其分为肝细胞型肝癌、胆管细胞型肝癌、混合型肝癌三组,采用SPSS统计软件分析各组之间超声特性的关系。(二)分别对34例肝细胞型肝癌、25例胆管细胞型肝癌术后复发患者行经皮肝穿刺瘤内注射无水酒精治疗并进行随访,观察其治疗效果,对比分析两组差异。
结果:(一)按照病理结果分组对术前肿瘤超声特性统计结果进行卡方检验,得到如下结果:肿瘤回声强弱P=0.085,肿瘤位置P=0.024,肿瘤边界清与否P=0.001,肿瘤数目P=0.402,患者性别分布P=0.005。不同病理组之间肿瘤的位置、边界清晰度以及患者性别分布有统计学意义,肿瘤超声回声强度的分布和肿瘤数目无统计学意义。另外,根据肿瘤回声强弱进行分组并对其直径进行方差分析,可以得到P=0.000,即不同回声组的肿瘤直径之间有统计学差异。(二)对原发性肝癌术后复发患者行PEIT治疗并进行随访,观察其治疗效果,结果如下:肝细胞型肝癌组患者30例有效,有效率为88.24%(30/34),胆管细胞型肝癌组患者17例有效,有效率68%(17/25),进行卡方检验,p<0.05,即不同病理分型原发性肝癌术后复发患者行经皮肝穿刺瘤内注射无水酒精治疗疗效有统计学差异。
结论:(一)不同病理分型的原发性肝癌有不同的超声特性,肝细胞型肝癌、混合型肝癌、胆管细胞型肝癌依次呈现出左叶发生率增高,边界清楚度降低,女性患者增多的特性。肿瘤超声回声强度和其直径大小成正相关,平均直径相同的肝细胞型肝癌回声强度要高于胆管细胞型肝癌。(二)经皮肝穿刺瘤内注射无水酒精治疗肝细胞型肝癌患者术后复发肿瘤效果明显好于胆管细胞型肝癌患者,胆管细胞癌患者术后复发可合并使用其他治疗方法以增强疗效。
Objective To evaluate the ultrasounic characteristics and compare the therapeutic efficacy of percutaneous ethanol injection treatment(PEIT) of different histio-pathology types of primary liver cancer, wish to elevate the ability of applications of ordinary ultrasound examination in diagnosis and treatment of primary liver cancer. Methods (1) Retrospective analyze the preoperative ultrasound examination results including the echo intensity、tumor locality、definition of tumor edge、tumor numbers and distribution of gender of 552 cases of pimary liver cancer in Eastern Hepatobiliary Surgery Hospital from April to October in 2007 who have been operatived later,divide them to three groups as hepatocellular carcinoma(HCC)、Intrahepatic cholangiocarcinoma (ICC) and mixed hepatic carcinoma according to the histio-pathology types after operating and get the correlation ship of every group through SPSS statistic software.(2) choose and follow-up to visit 34 HCC patients and 25 ICC patients who were all postop and had recurrence tumor(diameter≤3cm and numbers≤3 ) those had been treated by PEIT. Compare and analyze the therapeutic efficacy. Results Statistic the ultrasound characteristics according to the histo-pathology results using chi-square test and get the results as follows:P(echo intensity)=0.085、P (tumor locality)=0.024、P(definition of tumor edge)=0.001、P(distribution of gender)=0.005、P ( tumor numbers ) =0.402。The tumor locality、definition of tumor edge、distribution of gender of different histo-pathology types have statistical signification. The echo intensity and tumor numbers haven’t statistic signification. But if divid the groups as the echo intensity and statistic the tumor diameters using ANOVA, we can get P=0.000, so the diameter of different echo intensity groups has statistical signification. (2) Analyze therapeutic efficacy of PEIT on the postop patients who have recurrence tumor (diameter≤3cm and numbers≤3), we can get the results as following: 30 cases were effective and the efficiency rate was 88.24% of HCC (30/34), 17 cases were effective and the efficiency rate was 68% of ICC (17/25). Through Chi-square test, there have signification of statistics ( p<0.05). Conclusion (1) Different histio-pathology types of primary liver cancer have different ultrasound characteristics. The incidence on the left lobe of liver and the incidence rates on women patients is increasing , the boundary definition is decreasing by turns of HCC、mixed hepatic carcinoma and ICC。The echo intensity is increasing with the diameter of tumor increasing. HCC′s echo intensity is higher than ICC′s when their diameter is same .(2) The therapeutic efficacy of PEIT on the recurence tumor of postop patient of HCC is superior to ICC. It is correlative with the pathological characteristics of HCC and ICC. So other treating measure should be taken on the recurrence tumor of ICC to elevate its therapeutic efficacy.
方法:(一)回顾性分析了2007年4月至10月期间在我院行手术治疗的552例原发性肝癌患者术前超声检查结果,统计肿瘤回声强弱、肿瘤位置、肿瘤边界是否清晰、肿瘤数目等超声特性,按照术后病理结果将其分为肝细胞型肝癌、胆管细胞型肝癌、混合型肝癌三组,采用SPSS统计软件分析各组之间超声特性的关系。(二)分别对34例肝细胞型肝癌、25例胆管细胞型肝癌术后复发患者行经皮肝穿刺瘤内注射无水酒精治疗并进行随访,观察其治疗效果,对比分析两组差异。
结果:(一)按照病理结果分组对术前肿瘤超声特性统计结果进行卡方检验,得到如下结果:肿瘤回声强弱P=0.085,肿瘤位置P=0.024,肿瘤边界清与否P=0.001,肿瘤数目P=0.402,患者性别分布P=0.005。不同病理组之间肿瘤的位置、边界清晰度以及患者性别分布有统计学意义,肿瘤超声回声强度的分布和肿瘤数目无统计学意义。另外,根据肿瘤回声强弱进行分组并对其直径进行方差分析,可以得到P=0.000,即不同回声组的肿瘤直径之间有统计学差异。(二)对原发性肝癌术后复发患者行PEIT治疗并进行随访,观察其治疗效果,结果如下:肝细胞型肝癌组患者30例有效,有效率为88.24%(30/34),胆管细胞型肝癌组患者17例有效,有效率68%(17/25),进行卡方检验,p<0.05,即不同病理分型原发性肝癌术后复发患者行经皮肝穿刺瘤内注射无水酒精治疗疗效有统计学差异。
结论:(一)不同病理分型的原发性肝癌有不同的超声特性,肝细胞型肝癌、混合型肝癌、胆管细胞型肝癌依次呈现出左叶发生率增高,边界清楚度降低,女性患者增多的特性。肿瘤超声回声强度和其直径大小成正相关,平均直径相同的肝细胞型肝癌回声强度要高于胆管细胞型肝癌。(二)经皮肝穿刺瘤内注射无水酒精治疗肝细胞型肝癌患者术后复发肿瘤效果明显好于胆管细胞型肝癌患者,胆管细胞癌患者术后复发可合并使用其他治疗方法以增强疗效。
Objective To evaluate the ultrasounic characteristics and compare the therapeutic efficacy of percutaneous ethanol injection treatment(PEIT) of different histio-pathology types of primary liver cancer, wish to elevate the ability of applications of ordinary ultrasound examination in diagnosis and treatment of primary liver cancer. Methods (1) Retrospective analyze the preoperative ultrasound examination results including the echo intensity、tumor locality、definition of tumor edge、tumor numbers and distribution of gender of 552 cases of pimary liver cancer in Eastern Hepatobiliary Surgery Hospital from April to October in 2007 who have been operatived later,divide them to three groups as hepatocellular carcinoma(HCC)、Intrahepatic cholangiocarcinoma (ICC) and mixed hepatic carcinoma according to the histio-pathology types after operating and get the correlation ship of every group through SPSS statistic software.(2) choose and follow-up to visit 34 HCC patients and 25 ICC patients who were all postop and had recurrence tumor(diameter≤3cm and numbers≤3 ) those had been treated by PEIT. Compare and analyze the therapeutic efficacy. Results Statistic the ultrasound characteristics according to the histo-pathology results using chi-square test and get the results as follows:P(echo intensity)=0.085、P (tumor locality)=0.024、P(definition of tumor edge)=0.001、P(distribution of gender)=0.005、P ( tumor numbers ) =0.402。The tumor locality、definition of tumor edge、distribution of gender of different histo-pathology types have statistical signification. The echo intensity and tumor numbers haven’t statistic signification. But if divid the groups as the echo intensity and statistic the tumor diameters using ANOVA, we can get P=0.000, so the diameter of different echo intensity groups has statistical signification. (2) Analyze therapeutic efficacy of PEIT on the postop patients who have recurrence tumor (diameter≤3cm and numbers≤3), we can get the results as following: 30 cases were effective and the efficiency rate was 88.24% of HCC (30/34), 17 cases were effective and the efficiency rate was 68% of ICC (17/25). Through Chi-square test, there have signification of statistics ( p<0.05). Conclusion (1) Different histio-pathology types of primary liver cancer have different ultrasound characteristics. The incidence on the left lobe of liver and the incidence rates on women patients is increasing , the boundary definition is decreasing by turns of HCC、mixed hepatic carcinoma and ICC。The echo intensity is increasing with the diameter of tumor increasing. HCC′s echo intensity is higher than ICC′s when their diameter is same .(2) The therapeutic efficacy of PEIT on the recurence tumor of postop patient of HCC is superior to ICC. It is correlative with the pathological characteristics of HCC and ICC. So other treating measure should be taken on the recurrence tumor of ICC to elevate its therapeutic efficacy.
引文
1. Schurr R SU, Schuppan D . Increased incidence of hepatocellular and intrahepatic cholangiocellular carcinoma in northeast Germany. Dtsch Med Wochenschr 2006;131:7.
2. Staib F HS, Hofseth LJ, Wang XW. TP53 and liver carcinogenesis. Human mutation 2003;21:201-216.
3.朱明华.肝脏肿瘤病理学展望.中华病理学杂志2007;36:721-722.
4. Calmus Y. Liver transplantation for cancer. La Revue du praticien 2008;58:1745-1748.
5. Martin R, Jarnagin W. Intrahepatic cholangiocarcinoma. Current management. Minerva chirurgica 2003;58:469-478.
6. Aishima S, Taguchi K,Sugimachi K.. The role of thymidine phosphorylase and thrombospondin-1 in angiogenesis and progression of intrahepatic cholangiocarcinoma Int J Surg PathoL 2002;10.:47-56.
7. Yancopoulos GD, Davis S, Gale NW. Vascular-specific growth factors and blood vessel formation. Nature 2000;407:242-248.
8. Davis S GN, Davis S,Gale NW. Vascular-specific growth factors and blood vessel formation. Nature 2000;407:242-248.
9. Kim HJ,Lee Kim EK. Expression of cyclooxygenase-2 in cholangioearcinoma:correlation with clinicopathological features and prognosis. J Gastroenterol Hepatol 2004;19:582-588.
10. Makino Y YA, Kimoto T. The influence of perioperative blood transfusion on intrahepatic recurrence after curative resection of hepatocellular carcinoma. Am J Gastroenterol 2000;95:1294-1300.
11. Poon RT CK, Cheung ST. Clinical significance of thrombospondin 1 expression in hepatocelular carcinoma. Clin Cancer Res 2004;10:4150-4157..
12.周永昌,郭万学.超声医学.北京:科学技术文献出版社, 2003.
13. Guo ZJ, Li Q, He K. Diagnosis and treatment of hepatic cholangiocarcinoma: report of 52 cases. Hepatobiliary Pancreat Dis Int 2003;2:62-65.
14.郭佳,杨甲梅,陈汉.超声介入无水酒精瘤内注射治疗肝癌的意义(附2000例报告).中国实用外科杂志2001;12:494-495.
15. Kitaoka M. Changes in interventional treatment--from the viewpoint of percutaneous ethanol injection therapy. Ther Apher Dial 2008;12 Suppl 1:S16-20.
16. Narvaez-Lugo J, Caceres WW, Toro DH. Transcatheter arterial chemoembolization and percutaneous ethanol injection for Hepatocellular carcinoma: a retrospective review of the Veterans Affairs Caribbean Healthcare System. Cancer Control 2008;15:80-85.
1. Schurr R SU, Schuppan D . Increased incidence of hepatocellular and intrahepatic cholangiocellular carcinoma in northeast Germany. Dtsch Med Wochenschr 2006;131:7.
2.朱明华.肝脏肿瘤病理学展望.中华病理学杂志2007;36:721-722.
3. Davis S GN, Davis S,Gale NW,et a1. Vascular-specific growth factors and blood vessel formation. Nature 2000;407:242-248.
4. Aishima S , Taguchi K , Sugimachi K. The role of thymidine phosphorylase and thrombospondin-1 in angiogenesis and progression of intrahepatic cholangiocarcinoma Int J Surg PathoL 2002;10.:47-56.
5. Kim HJ,Lee Kim EK . Expression of cyclooxygenase-2 in cholangioearcinoma:correlation with clinicopathological features and prognosis. J Gastroenterol Hepatol 2004;19:582-588.
6. Makino Y YA, Kimoto T. The influence of perioperative blood transfusion on intrahepatic recurrence after curative resection of hepatocellular carcinoma. Am J Gastroenterol 2000;95:1294-1300.
7. Poon RT CK, Cheung ST. Clinical significance of thrombospondin 1 expression in hepatocelular carcinoma. Clin Cancer Res 2004;10:4150-4157..
8.许达生.肝细胞癌临床CT诊断.北京:世界图书出版公司, 2003.
9. Guo ZJ, Li Q, He K. Diagnosis and treatment of hepatic cholangiocarcinoma: report of 52 cases. Hepatobiliary Pancreat Dis Int 2003;2:62-65.
10. Dreyer C, Le Tourneau C, Faivre S, Qian Z, Degos F, Vuillerme MP . [Cholangiocarcinoma: epidemiology and global management]. La Revue de medecine interne / fondee 2008;29:642-651.
11. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007;132:2557-2576.
12.周俭,吴志全,樊嘉,等.胆管细胞癌临床特点及其与肝细胞肝癌的比较.中国普通外科杂志2000;15:330.
13.何振平,马宽生,王曙光,等.肝内胆管癌的临床比例特征与外科治疗.中华肝胆外科杂志2002;8:475-477.
14. Franco D, Usatoff V. Surgery for cholangiocarcinoma. Hepato-gastroenterology 2001;48:53-55.
15. Renshaw AA, Haja J, Wilbur DC, Miller TR. Fine-needle aspirates of hepatocellular carcinoma that are misclassified as adenocarcinoma: correlating cytologic features and performance in the College of American Pathologists Nongynecologic Cytology Program. Archives of pathology & laboratory medicine 2006;130:19-22.
16.曹晓伟,季峻松,陈婷,等.肝癌临床病理特征与肝移植术后预后的多因素相关分析.第二军医大学学报2008:1086-1090.
17.董敬东(综述),王莉芬(审校).原发性肝癌影像学特征与病理学关系的研究进展.大连医科大学学报2005:474-476.
18.陆东东.乙型肝炎病毒致肝癌机理.现代康复1998:260-260.
19.贺小虎,王炳元.嗜酒与乙型肝炎病毒感染的临床特征.实用肝脏病杂志2008:276-277.
20.俞顺章,穆丽娜.乙型肝炎与肝癌.上海预防医学2005:417-418.
21. Wu GC, Zhou WP, Zhao YR, Guo SH, Wang ZY, Zou SB . The natural history of chronic hepatitis B: a retrospective study. Hepatobiliary Pancreat Dis Int 2003;2:566-570.
22. Szabo G, Dolganiuc A, Mandrekar P, White B. Inhibition of antigen-presenting cell functions by alcohol: implications for hepatitis C virus infection. Alcohol (Fayetteville, NY 2004;33:241-249.
23. Szabo G, Aloman C, Polyak SJ, Weinman SA, Wands J, Zakhari S. Hepatitis C infection and alcohol use: A dangerous mix for the liver and antiviral immunity. Alcoholism, clinical and experimental research 2006;30:709-719.
24. Brown LA, Cook RT, Jerrells TR, Kolls JK, Nagy LE, Szabo G, . Acute and chronic alcohol abuse modulate immunity. Alcoholism, clinical and experimental research 2006;30:1624-1631.
25. Trappoliere M, Tuccillo C, Federico A, Di Leva A, Niosi M, D'Alessio C. The treatment of NAFLD. European Review for Medical & Pharmacological Sciences 2005;9:299-304.
26.周永健,李瑜元,马金香,等.性别、肥胖与非酒精性脂肪肝患病关系调查.广东医学2008:1392-1394.
27.清水一郎,姚桢.肝硬化与肝癌的性别差异.日本医学介绍2001:223-224.
28. Guo M, Gong L, He L, Lehman-McKeeman L, Wan YJ. Hepatocyte RXRalpha deficiency in matured and aged mice: impact on the expression of cancer-related hepatic genes in a gender-specific manner. BMC Genomics 2008;9:403.
29. Naugler WE, Sakurai T, Kim S . Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production.[see comment]. Science 2007;317:121-124.
30. Chen PH, Lin YC, Tu HP . Important prognostic factors for the long-term survival of subjects with primary liver cancer in Taiwan: a hyperendemic area. European Journal of Cancer 2007;43:1076-1084.
31.王晓光,刘延君.小肝癌的超声回声特性与病理组织学的对比分析.中国医科大学学报2002:289-291.
32.王知力,董宝玮,梁萍.肝细胞肝癌灰阶超声强度与其组织病理相关性的研究.中国超声医学杂志2004:602-605.
33. Davis PL, Filly RA, Goerke J. In vitro demonstration of an echogenic emulsion: relationship of lipid particle size to echo detection. Journal of Clinical Ultrasound 1981;9:263-266.
34. Davis PL, Filly RA, Goerke J. Echogenicity caused by stable microbubbles in a protein-lipid emulsion. Journal of Clinical Ultrasound 1981;9:249-252.
35. Mansfield SD, Barakat O, Charnley RM, Jaques BC, O'Suilleabhain CB, Atherton PJ . Management of hilar cholangiocarcinoma in the North of England: pathology, treatment, and outcome. World Journal of Gastroenterology 2005;11:7625-7630.
1. Eguchi S, Kanematsu T, Arii S, Okazaki M, Okita K, Omata M . Comparison of the outcomes between an anatomical subsegmentectomy and a non-anatomical minor hepatectomy for single hepatocellular carcinomas based on a Japanese nationwide survey. Surgery 2008;143:469-475.
2. Livraghi T. Radiofrequency ablation, PEIT, and TACE for hepatocellular carcinoma. Journal of hepato-biliary-pancreatic surgery 2003;10:67-76.
3. Takayasu K, Arii S, Ikai I, Omata M, Okita K, Ichida T . Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 2006;131:461-469.
4.周永昌,郭万学.超声医学.北京:科学技术文献出版社, 2003.
5.李波,吴孟超.术后复发性肝癌瘤内酒精注射治疗.中华肿瘤杂志1995:371-373.
6.郭佳,杨甲梅,陈汉,等.超声介入无水酒精瘤内注射治疗肝癌的意义(附2000例报告).中国实用外科杂志2001;12:494-495.
7. Narvaez-Lugo J, Caceres WW, Toro DH, Perez-Gonzalez MR, Almodovar AA, Maldonado-Mercado AM. Transcatheter arterial chemoembolization and percutaneous ethanol injection for Hepatocellular carcinoma: a retrospective review of the Veterans Affairs Caribbean Healthcare System. Cancer Control 2008;15:80-85.
8.林礼务,林学英,薛恩生,何以敉,高上达,林晓东,等.超声介入无水乙醇量化治疗合并肝硬化的复发性肝癌的临床研究.中国医学影像技术2006:117-120.
9. Ochiai T, Sonoyama T, Kikuchi S, Ichikawa D, Fujiwara H, Okamoto K . [Multiple hepatocellular carcinomas successfully treated by combined therapies]. Gan to kagaku ryoho 2005;32:1809-1811.
10.张丽,郭佳.原发性肝癌超声特性和组织病理学分型相关性分析.中国超声医学杂志2009;25:149-151.
11. Renshaw AA, Wang E, Haja J, Wilbur D, Henry MR, Hughes JH. Fine-needle aspiration of papillary thyroid carcinoma: distinguishing between cases that performed well and those that performed poorly in the College of American Pathologists Nongynecologic Cytology Program. Archives of pathology & laboratory medicine 2006;130:452-455.
12.周俭,吴志全,樊嘉,等.胆管细胞癌临床特点及其与肝细胞肝癌的比较.中国普通外科杂志2000;15:330.
13. Dreyer C, Le Tourneau C, Faivre S, Qian Z, Degos F, Vuillerme MP . [Cholangiocarcinoma: epidemiology and global management]. La Revue de medecine interne / fondee 2008;29:642-651.
14. Franco D, Usatoff V. Surgery for cholangiocarcinoma. Hepato-gastroenterology 2001;48:53-55.
15. Renshaw AA, Haja J, Wilbur DC, Miller TR. Fine-needle aspirates of hepatocellular carcinoma that are misclassified as adenocarcinoma: correlating cytologic features and performance in the College of American Pathologists Nongynecologic Cytology Program. Archives of pathology & laboratory medicine 2006;130:19-22.
16.曹晓伟,季峻松,陈婷,等.肝癌临床病理特征与肝移植术后预后的多因素相关分析.第二军医大学学报2008:1086-1090.
17. Seki T, Nonaka T, Kubota Y, Mizuno T, Sameshima Y. Ultrasonically guided percutaneous ethanol injection therapy for hepatocellular carcinoma. The American journal of gastroenterology 1989;84:1400-1407.
18. Maetani Y, Itoh K, Watanabe C, Shibata T, Ametani F, Yamabe H. MR imaging of intrahepatic cholangiocarcinoma with pathologic correlation. Ajr 2001;176:1499-1507.
19.朱明华.肝脏肿瘤病理学展望.中华病理学杂志2007;36:721-722.
1. Schurr R SU, Schuppan D . Increased incidence of hepatocellular and intrahepatic cholangiocellular carcinoma in northeast Germany. Dtsch Med Wochenschr 2006;131:7.
2.朱明华.肝脏肿瘤病理学展望.中华病理学杂志2007;36:721-722.
3.杨红梅.“晕圈”在超声诊断原发性肝癌中的价值.中国基层医药2006;13:1639-1640.
4.周永昌,郭万学.超声医学.北京:科学技术文献出版社, 2003.
5. Kadoya MD MM, Takashirna MD. Hepa-tocellular carcinoma: Correlation of M R imaging and histopathologic findings. Radiology 1992;183:819.
6.董敬东(综述),王莉芬(审校).原发性肝癌影像学特征与病理学关系的研究进展.大连医科大学学报2005:474-476.
7. Itoh Y AK. Relationship between echo level and histologic characteristics in small hepatocellular carcinomas. Clin Ultrasound 1998;26:295-301.
8.王知力,董宝玮,梁萍,于晓玲,于德江,张晶.肝细胞肝癌灰阶超声强度与其组织病理相关性的研究.中国超声医学杂志2004:602-605.
9. Davis PL, Filly RA, Goerke J. In vitro demonstration of an echogenic emulsion: relationship of lipid particle size to echo detection. J Clin Ultrasound 1981;9:263-266.
10. Kenmochi K SS, Kojiro M. Relationship of histologic grade of hepatoceIluIar carcioma(HCC)to tumor size,and demonstration of tumor cells of multiple different grades in single small HCC. Liver 1987;7:18-26.
11. Sugihara S NO, Kojiro M . The morphologic transition in hepatoceIlular carcinoma. Cancer Control 1992;15:1488-1492.
12.李瑞珍,何炜.小肝癌的超声多普勒显像与病理分级相关性的研究.医学临床研究2004 21:214-217.
13. Bude RO RJ, Adler RS. Power versus conventional color Doppler sonography : comparison in the depiction of normal intrarenal vasculature. Radiology 1994;192:777-780.
14. Koito K, Namieno T, Morita K. Differential diagnosis of small hepatocellular carcinoma and adenomatous hyperplasia with power Doppler sonography. Ajr 1998;170:157-161.
15. Imamura H, Matsuyama Y, Tanaka E, Ohkubo T, Hasegawa K, Miyagawa S, . Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. Journal of hepatology 2003;38:200-207.
16. Yamamoto T, Hirohashi K, Kaneda K, Ikebe T, Mikami S, Uenishi T . Relationship of the microvascular type to the tumor size, arterialization and dedifferentiation of human hepatocellular carcinoma. Jpn J Cancer Res 2001;92:1207-1213.
17. Sato S, Shiratori Y, Imamura M, Obi S, Shiina S, Akahane M . Re-appearance of power Doppler signals in the tumor nodules of hepatocellular carcinoma after transarterial embolization reflects residual viable tumor cells: histological confirmation. Hepato-gastroenterology 2004;51:56-61.
18. Battula N, Madanur M, Priest O, Srinivasan P, O'Grady J, Heneghan MA . Spontaneous rupture of hepatocellular carcinoma: a Western experience. American journal of surgery 2009;197:164-167.
19. Al-Mashat FM, Sibiany AM, Kashgari RH, Maimani AA, Al-Radi AO, Balawy IA . Spontaneous rupture of hepatocellular carcinoma. Saudi medical journal 2002;23:866-870.
20. Zhu LX, Wang GS, Fan ST. Spontaneous rupture of hepatocellular carcinoma. The British journal of surgery 1996;83:602-607.
21. Zhu LX, Geng XP, Fan SD. Ultrastructure study on patients with spontaneous rupture of hepatocellular carcinoma. Zhonghua wai ke za zhi [Chinese journal of surgery] 2006;44:161-164.
22.高秀荣,迟玉花.肝癌自发性破裂出血的超声显像诊断.中国超声医学杂志1997:69-70.
23. Lai EC, Lau WY. Spontaneous rupture of hepatocellular carcinoma: a systematic review. Arch Surg 2006;141:191-198.
24. Minagawa M, Makuuchi M, Takayama T, Ohtomo K. Selection criteria for hepatectomy in patients with hepatocellular carcinoma and portal vein tumor thrombus. Annals of surgery 2001;233:379-384.
25.杨维秀,陈汉荣.彩色多普勒血流显像对血管内血栓和瘤栓的鉴别诊断.同济医科大学学报1997:401-402,408.
26. Ricci P, Cantisani V, Biancari F, Drud FM, Coniglio M, Di Filippo A . Contrast-enhanced color Doppler US in malignant portal vein thrombosis. Acta Radiol 2000;41:470-473.
27. Ueno N, Kawamura H, Takahashi H, Fujisawa N, Yoneda M, Kirikoshi H . Characterization of portal vein thrombus with the use of contrast-enhanced sonography. J Ultrasound Med 2006;25:1147-1152.
28. Tarantino L, Francica G, Sordelli I, Esposito F, Giorgio A, Sorrentino P. Diagnosis of benign and malignant portal vein thrombosis in cirrhotic patients with hepatocellular carcinoma: color Doppler US, contrast-enhanced US, and fine-needle biopsy. Abdominal imaging 2006;31:537-544.
29. Tola M, Yurdakul M, Okten S, Ozdemir E, Cumhur T. Diagnosis of arterial occlusive disease of the upper extremities: comparison of color duplex sonography and angiography. J Clin Ultrasound 2003;31:407-411.
30.罗淑荣,段云友,等.彩超诊断门脉癌栓.中国医学影像技术2002:59-60.
31. Zech CJ, Schoenberg SO, Reiser M, Helmberger T. Cross-sectional imaging of biliary tumors: current clinical status and future developments. European radiology 2004;14:1174-1187.
32. Hung MC, Wu HS, Lee YT, Hsu CH, Chou DA, Huang MH. Intraperitoneal metastasis ofhepatocellular carcinoma after spontaneous rupture: a case report. World J Gastroenterol 2008;14:3927-3931.
33.郭春苗,王静意. B超在以胆管癌栓为主要征象的肝癌中的诊断价值.临床医学1996:6-7.
1. Eguchi S, Kanematsu T, Arii S, Okazaki M, Okita K, Omata M, . Comparison of the outcomes between an anatomical subsegmentectomy and a non-anatomical minor hepatectomy for single hepatocellular carcinomas based on a Japanese nationwide survey. Surgery 2008;143:469-475.
2. Livraghi T. Radiofrequency ablation, PEIT, and TACE for hepatocellular carcinoma. Journal of hepato-biliary-pancreatic surgery 2003;10:67-76.
3.杨健,杨超.原发性肝癌术后复发的再治疗.江西医药2008:300-302.
4.周永昌,郭万学.超声医学.北京:科学技术文献出版社, 2003.
5.李波,吴孟超.术后复发性肝癌瘤内酒精注射治疗.中华肿瘤杂志1995:371-373.
6. Koike Y, Shiratori Y, Sato S, Obi S, Teratani T, Imamura M, . Des-gamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients. Cancer 2001;91:561-569.
7. Teratani T, Ishikawa T, Shiratori Y, Shiina S, Yoshida H, Imamura M, . Hepatocellular carcinoma in elderly patients: beneficial therapeutic efficacy using percutaneous ethanol injection therapy. Cancer 2002;95:816-823.
8. Seki T, Nonaka T, Kubota Y, Mizuno T, Sameshima Y. Ultrasonically guided percutaneous ethanol injection therapy for hepatocellular carcinoma. The American journal of gastroenterology 1989;84:1400-1407.
9. Lin LW, Lin XY, He YM, Gao SD, Lin XD. Biological characteristics of HCC by ultrasound-guided aspiration biopsy and its clinical application. World J Gastroenterol 2003;9:941-945.
10. Rustemovic N, Vucelic B, Opacic M, Ostojic R, Pulanic R, Petrovecki M, . Palliative treatment of hepatocellular carcinoma with percutaneous ethanol injection using tumor's feeding artery occlusion under the ultrasonic color Doppler guidance. Collegium antropologicum 2004;28:781-791.
11.杨嘉嘉(综述),林礼务(审校).超声介入注射无水乙醇治疗肝癌的研究现状及进展.中国医学影像技术2008:293-296.
12. Nishiharu T, Maeda N, Hara M, Yamashita Y. [Usefulness of enhanced ultrasonography after administration of intravenous contrast agent in the evaluation of therapeutic effect in treatment of hepatocellular carcinoma, and efficacy of percutaneous ethanol injection therapy (PEIT) for residual tumor]. Nihon Igaku Hoshasen Gakkai zasshi 2001;61:790-795.
13. Numata K, Isozaki T, Ozawa Y, Sakaguchi T, Kiba T, Kubota T, . Percutaneous ablation therapy guided by contrast-enhanced sonography for patients with hepatocellular carcinoma. Ajr 2003;180:143-149.
14. Ho CS, Kachura JR, Gallinger S, Grant D, Greig P, McGilvray I, . Percutaneous ethanol injection of unresectable medium-to-large-sized hepatomas using a multipronged needle: efficacy and safety. Cardiovascular and interventional radiology 2007;30:241-247.
15. Tanikawa K, Majima Y. Percutaneous ethanol injection therapy for recurrent hepatocellular carcinoma. Hepato-gastroenterology 1993;40:324-327.
16. Shiratori Y, Shiina S, Teratani T, Imamura M, Obi S, Sato S, . Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Annals of internal medicine 2003;138:299-306.
17. Ferlitsch A, Kreil A, Bauer E, Schmidinger H, Schillinger M, Gangl A, . Bradycardia and sinus arrest during percutaneous ethanol injection therapy for hepatocellular carcinoma. European journal of clinical investigation 2004;34:218-223.
18. Noda T, Nagano H, Murakami M, Kobayashi S, Marubashi S, Miyamoto A, . [Surgical treatment for peritoneal seeding and needle-tract implantation of hepatocellular carcinoma after ultrasound-guided percutaneous puncture]. Gan to kagaku ryoho 2007;34:2080-2083.
19. Chan RP, Asch M, Kachura J, Ho CS, Greig P, Langer B, . Radiofrequency ablation of malignant hepatic neoplasms. Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes 2002;53:272-278.
20. Lencioni R, Crocetti L. Radiofrequency ablation of liver cancer. Techniques in vascular and interventional radiology 2007;10:38-46.
21.杜锡林,马庆久,褚延魁,高德明,杨媛,臧莉,等.射频消融(Rfa)治疗肝癌的临床研究.肝胆外科杂志2008:260-262.
22.王妍(综述),任正刚(审校).射频治疗肝癌术后复发的相关因素.中国肿瘤临床2008:411-414.
23. Kondo Y, Yoshida H, Tateishi R, Shiina S, Kawabe T, Omata M. Percutaneous radiofrequency ablation of liver cancer in the hepatic dome using the intrapleural fluid infusion technique. The British journal of surgery 2008;95:996-1004.
24. Weinberg BD, Blanco E, Lempka SF, Anderson JM, Exner AA, Gao J. Combined radiofrequency ablation and doxorubicin-eluting polymer implants for liver cancer treatment. Journal of biomedical materials research 2007;81:205-213.
25. Helton WS. Minimizing complications with radiofrequency ablation for liver cancer: the importance of properly controlled clinical trials and standardized reporting. Annals of surgery 2004;239:459-463.
26. Ma K, Min C, Ian HX, Jiahong D. Prevention and cure of complications from multiple-electrode radiofrequency treatment of liver tumors. Digestive diseases (Basel, Switzerland)2001;19:364-366.
27. Tsui SL, Lee AK, Lui SK, Poon RT, Fan ST. Acute intraoperative hemolysis and hemoglobinuria during radiofrequency ablation of hepatocellular carcinoma. Hepato-gastroenterology 2003;50:526-529.
28. Meloni MF, Goldberg SN, Moser V, Piazza G, Livraghi T. Colonic perforation and abscess following radiofrequency ablation treatment of hepatoma. Eur J Ultrasound 2002;15:73-76.
29.夏景林,任正刚,叶胜龙,干育红,王艳红,张博恒.肝癌射频消融治疗严重或少见并发症分析.中国微创外科杂志2005:268-270.
30. Jaskolka JD, Asch MR, Kachura JR, Ho CS, Ossip M, Wong F . Needle tract seeding after radiofrequency ablation of hepatic tumors. J Vasc Interv Radiol 2005;16:485-491.
31.刘元水,郑晓寰.原发性肝癌的冷冻消融治疗.山东医药2008;48:102-103.
32. Hinshaw JL, Lee FT, Jr. Cryoablation for liver cancer. Techniques in vascular and interventional radiology 2007;10:47-57.
33. Hu KW, Li QW, Zuo MH, Sun T, Jiang M. Clinical observation on the combined treatment of
57 cases of non-small cell lung cancer using argon-helium cryosurgery and Chinese herbal medicine. Chinese journal of integrative medicine 2007;13:224-227.
34.胡士杰,吴健雄,荣维淇,祁付珍,朱怀宇.经皮微波凝固治疗肝癌的研究进展.中国肿瘤临床与康复2005;12:471-472.
35. Heisterkamp J, van Hillegersberg R, Ijzermans JN. Interstitial laser coagulation for hepatic tumours. The British journal of surgery 1999;86:293-304.
36. Goldberg SN. Comparison of techniques for image-guided ablation of focal liver tumors. Radiology 2002;223:304-307.
37. Shibata T, Morita T, Okuyama M, Kitada M, Tsukahara Y, Ikeda K . Comparison of microwave coagulation using a new type electrode with radiofrequency ablation in the liver of living animals. Gan to kagaku ryoho 2001;28:1595-1598.
38. Satoi S, Kamiyama Y, Matsui Y, Kitade H, Kaibori M, Yamamoto H. Clinical outcome of 214 liver resections using microwave tissue coagulation. Hepato-gastroenterology 2005;52:1180-1185.
39. Aramaki M, Kawano K, Ohno T, Sasaki A, Tahara K, Kai S. Microwave coagulation therapy for unresectable hepatocellular carcinoma. Hepato-gastroenterology 2004;51:1784-1787.
40.李东方,宋晓红,梁晓玲,邢超,张蓉蓉.腹壁烫伤——肝癌微波凝固治疗中不可忽视的并发症.中华肝胆外科杂志2006;12:392-392.
41.张丽,郭佳.原发性肝癌超声特性和组织病理学分型相关性分析.中国超声医学杂志2009;25:149-151.
42. Watanabe Y, Sato M, Abe Y, Horiuchi S, Kito K, Kimura K . Laparoscopic microwave coagulo-necrotic therapy for hepatocellular carcinoma: a feasible study of an alternative option for poor-risk patients. Journal of laparoendoscopic surgery 1995;5:169-175.
43. Yamakado K, Nakatsuka A, Takaki H, Mori Y, Tonouchi H, Kusunoki M . Prospective study of arterial infusion chemotherapy followed by radiofrequency ablation for the treatment of liver metastasis of gastric cancer. J Vasc Interv Radiol 2005;16:1747-1751.
44. Lin LW, Sun Y, He YM, Gao SD, Xue ES, Lin XD. Percutaneous intratumoral injection of traditional Chinese herbal compound medicine Star-99 in treatment of hepatocellular carcinoma of mice. Hepatobiliary Pancreat Dis Int 2004;3:49-54.
2. Staib F HS, Hofseth LJ, Wang XW. TP53 and liver carcinogenesis. Human mutation 2003;21:201-216.
3.朱明华.肝脏肿瘤病理学展望.中华病理学杂志2007;36:721-722.
4. Calmus Y. Liver transplantation for cancer. La Revue du praticien 2008;58:1745-1748.
5. Martin R, Jarnagin W. Intrahepatic cholangiocarcinoma. Current management. Minerva chirurgica 2003;58:469-478.
6. Aishima S, Taguchi K,Sugimachi K.. The role of thymidine phosphorylase and thrombospondin-1 in angiogenesis and progression of intrahepatic cholangiocarcinoma Int J Surg PathoL 2002;10.:47-56.
7. Yancopoulos GD, Davis S, Gale NW. Vascular-specific growth factors and blood vessel formation. Nature 2000;407:242-248.
8. Davis S GN, Davis S,Gale NW. Vascular-specific growth factors and blood vessel formation. Nature 2000;407:242-248.
9. Kim HJ,Lee Kim EK. Expression of cyclooxygenase-2 in cholangioearcinoma:correlation with clinicopathological features and prognosis. J Gastroenterol Hepatol 2004;19:582-588.
10. Makino Y YA, Kimoto T. The influence of perioperative blood transfusion on intrahepatic recurrence after curative resection of hepatocellular carcinoma. Am J Gastroenterol 2000;95:1294-1300.
11. Poon RT CK, Cheung ST. Clinical significance of thrombospondin 1 expression in hepatocelular carcinoma. Clin Cancer Res 2004;10:4150-4157..
12.周永昌,郭万学.超声医学.北京:科学技术文献出版社, 2003.
13. Guo ZJ, Li Q, He K. Diagnosis and treatment of hepatic cholangiocarcinoma: report of 52 cases. Hepatobiliary Pancreat Dis Int 2003;2:62-65.
14.郭佳,杨甲梅,陈汉.超声介入无水酒精瘤内注射治疗肝癌的意义(附2000例报告).中国实用外科杂志2001;12:494-495.
15. Kitaoka M. Changes in interventional treatment--from the viewpoint of percutaneous ethanol injection therapy. Ther Apher Dial 2008;12 Suppl 1:S16-20.
16. Narvaez-Lugo J, Caceres WW, Toro DH. Transcatheter arterial chemoembolization and percutaneous ethanol injection for Hepatocellular carcinoma: a retrospective review of the Veterans Affairs Caribbean Healthcare System. Cancer Control 2008;15:80-85.
1. Schurr R SU, Schuppan D . Increased incidence of hepatocellular and intrahepatic cholangiocellular carcinoma in northeast Germany. Dtsch Med Wochenschr 2006;131:7.
2.朱明华.肝脏肿瘤病理学展望.中华病理学杂志2007;36:721-722.
3. Davis S GN, Davis S,Gale NW,et a1. Vascular-specific growth factors and blood vessel formation. Nature 2000;407:242-248.
4. Aishima S , Taguchi K , Sugimachi K. The role of thymidine phosphorylase and thrombospondin-1 in angiogenesis and progression of intrahepatic cholangiocarcinoma Int J Surg PathoL 2002;10.:47-56.
5. Kim HJ,Lee Kim EK . Expression of cyclooxygenase-2 in cholangioearcinoma:correlation with clinicopathological features and prognosis. J Gastroenterol Hepatol 2004;19:582-588.
6. Makino Y YA, Kimoto T. The influence of perioperative blood transfusion on intrahepatic recurrence after curative resection of hepatocellular carcinoma. Am J Gastroenterol 2000;95:1294-1300.
7. Poon RT CK, Cheung ST. Clinical significance of thrombospondin 1 expression in hepatocelular carcinoma. Clin Cancer Res 2004;10:4150-4157..
8.许达生.肝细胞癌临床CT诊断.北京:世界图书出版公司, 2003.
9. Guo ZJ, Li Q, He K. Diagnosis and treatment of hepatic cholangiocarcinoma: report of 52 cases. Hepatobiliary Pancreat Dis Int 2003;2:62-65.
10. Dreyer C, Le Tourneau C, Faivre S, Qian Z, Degos F, Vuillerme MP . [Cholangiocarcinoma: epidemiology and global management]. La Revue de medecine interne / fondee 2008;29:642-651.
11. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007;132:2557-2576.
12.周俭,吴志全,樊嘉,等.胆管细胞癌临床特点及其与肝细胞肝癌的比较.中国普通外科杂志2000;15:330.
13.何振平,马宽生,王曙光,等.肝内胆管癌的临床比例特征与外科治疗.中华肝胆外科杂志2002;8:475-477.
14. Franco D, Usatoff V. Surgery for cholangiocarcinoma. Hepato-gastroenterology 2001;48:53-55.
15. Renshaw AA, Haja J, Wilbur DC, Miller TR. Fine-needle aspirates of hepatocellular carcinoma that are misclassified as adenocarcinoma: correlating cytologic features and performance in the College of American Pathologists Nongynecologic Cytology Program. Archives of pathology & laboratory medicine 2006;130:19-22.
16.曹晓伟,季峻松,陈婷,等.肝癌临床病理特征与肝移植术后预后的多因素相关分析.第二军医大学学报2008:1086-1090.
17.董敬东(综述),王莉芬(审校).原发性肝癌影像学特征与病理学关系的研究进展.大连医科大学学报2005:474-476.
18.陆东东.乙型肝炎病毒致肝癌机理.现代康复1998:260-260.
19.贺小虎,王炳元.嗜酒与乙型肝炎病毒感染的临床特征.实用肝脏病杂志2008:276-277.
20.俞顺章,穆丽娜.乙型肝炎与肝癌.上海预防医学2005:417-418.
21. Wu GC, Zhou WP, Zhao YR, Guo SH, Wang ZY, Zou SB . The natural history of chronic hepatitis B: a retrospective study. Hepatobiliary Pancreat Dis Int 2003;2:566-570.
22. Szabo G, Dolganiuc A, Mandrekar P, White B. Inhibition of antigen-presenting cell functions by alcohol: implications for hepatitis C virus infection. Alcohol (Fayetteville, NY 2004;33:241-249.
23. Szabo G, Aloman C, Polyak SJ, Weinman SA, Wands J, Zakhari S. Hepatitis C infection and alcohol use: A dangerous mix for the liver and antiviral immunity. Alcoholism, clinical and experimental research 2006;30:709-719.
24. Brown LA, Cook RT, Jerrells TR, Kolls JK, Nagy LE, Szabo G, . Acute and chronic alcohol abuse modulate immunity. Alcoholism, clinical and experimental research 2006;30:1624-1631.
25. Trappoliere M, Tuccillo C, Federico A, Di Leva A, Niosi M, D'Alessio C. The treatment of NAFLD. European Review for Medical & Pharmacological Sciences 2005;9:299-304.
26.周永健,李瑜元,马金香,等.性别、肥胖与非酒精性脂肪肝患病关系调查.广东医学2008:1392-1394.
27.清水一郎,姚桢.肝硬化与肝癌的性别差异.日本医学介绍2001:223-224.
28. Guo M, Gong L, He L, Lehman-McKeeman L, Wan YJ. Hepatocyte RXRalpha deficiency in matured and aged mice: impact on the expression of cancer-related hepatic genes in a gender-specific manner. BMC Genomics 2008;9:403.
29. Naugler WE, Sakurai T, Kim S . Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production.[see comment]. Science 2007;317:121-124.
30. Chen PH, Lin YC, Tu HP . Important prognostic factors for the long-term survival of subjects with primary liver cancer in Taiwan: a hyperendemic area. European Journal of Cancer 2007;43:1076-1084.
31.王晓光,刘延君.小肝癌的超声回声特性与病理组织学的对比分析.中国医科大学学报2002:289-291.
32.王知力,董宝玮,梁萍.肝细胞肝癌灰阶超声强度与其组织病理相关性的研究.中国超声医学杂志2004:602-605.
33. Davis PL, Filly RA, Goerke J. In vitro demonstration of an echogenic emulsion: relationship of lipid particle size to echo detection. Journal of Clinical Ultrasound 1981;9:263-266.
34. Davis PL, Filly RA, Goerke J. Echogenicity caused by stable microbubbles in a protein-lipid emulsion. Journal of Clinical Ultrasound 1981;9:249-252.
35. Mansfield SD, Barakat O, Charnley RM, Jaques BC, O'Suilleabhain CB, Atherton PJ . Management of hilar cholangiocarcinoma in the North of England: pathology, treatment, and outcome. World Journal of Gastroenterology 2005;11:7625-7630.
1. Eguchi S, Kanematsu T, Arii S, Okazaki M, Okita K, Omata M . Comparison of the outcomes between an anatomical subsegmentectomy and a non-anatomical minor hepatectomy for single hepatocellular carcinomas based on a Japanese nationwide survey. Surgery 2008;143:469-475.
2. Livraghi T. Radiofrequency ablation, PEIT, and TACE for hepatocellular carcinoma. Journal of hepato-biliary-pancreatic surgery 2003;10:67-76.
3. Takayasu K, Arii S, Ikai I, Omata M, Okita K, Ichida T . Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 2006;131:461-469.
4.周永昌,郭万学.超声医学.北京:科学技术文献出版社, 2003.
5.李波,吴孟超.术后复发性肝癌瘤内酒精注射治疗.中华肿瘤杂志1995:371-373.
6.郭佳,杨甲梅,陈汉,等.超声介入无水酒精瘤内注射治疗肝癌的意义(附2000例报告).中国实用外科杂志2001;12:494-495.
7. Narvaez-Lugo J, Caceres WW, Toro DH, Perez-Gonzalez MR, Almodovar AA, Maldonado-Mercado AM. Transcatheter arterial chemoembolization and percutaneous ethanol injection for Hepatocellular carcinoma: a retrospective review of the Veterans Affairs Caribbean Healthcare System. Cancer Control 2008;15:80-85.
8.林礼务,林学英,薛恩生,何以敉,高上达,林晓东,等.超声介入无水乙醇量化治疗合并肝硬化的复发性肝癌的临床研究.中国医学影像技术2006:117-120.
9. Ochiai T, Sonoyama T, Kikuchi S, Ichikawa D, Fujiwara H, Okamoto K . [Multiple hepatocellular carcinomas successfully treated by combined therapies]. Gan to kagaku ryoho 2005;32:1809-1811.
10.张丽,郭佳.原发性肝癌超声特性和组织病理学分型相关性分析.中国超声医学杂志2009;25:149-151.
11. Renshaw AA, Wang E, Haja J, Wilbur D, Henry MR, Hughes JH. Fine-needle aspiration of papillary thyroid carcinoma: distinguishing between cases that performed well and those that performed poorly in the College of American Pathologists Nongynecologic Cytology Program. Archives of pathology & laboratory medicine 2006;130:452-455.
12.周俭,吴志全,樊嘉,等.胆管细胞癌临床特点及其与肝细胞肝癌的比较.中国普通外科杂志2000;15:330.
13. Dreyer C, Le Tourneau C, Faivre S, Qian Z, Degos F, Vuillerme MP . [Cholangiocarcinoma: epidemiology and global management]. La Revue de medecine interne / fondee 2008;29:642-651.
14. Franco D, Usatoff V. Surgery for cholangiocarcinoma. Hepato-gastroenterology 2001;48:53-55.
15. Renshaw AA, Haja J, Wilbur DC, Miller TR. Fine-needle aspirates of hepatocellular carcinoma that are misclassified as adenocarcinoma: correlating cytologic features and performance in the College of American Pathologists Nongynecologic Cytology Program. Archives of pathology & laboratory medicine 2006;130:19-22.
16.曹晓伟,季峻松,陈婷,等.肝癌临床病理特征与肝移植术后预后的多因素相关分析.第二军医大学学报2008:1086-1090.
17. Seki T, Nonaka T, Kubota Y, Mizuno T, Sameshima Y. Ultrasonically guided percutaneous ethanol injection therapy for hepatocellular carcinoma. The American journal of gastroenterology 1989;84:1400-1407.
18. Maetani Y, Itoh K, Watanabe C, Shibata T, Ametani F, Yamabe H. MR imaging of intrahepatic cholangiocarcinoma with pathologic correlation. Ajr 2001;176:1499-1507.
19.朱明华.肝脏肿瘤病理学展望.中华病理学杂志2007;36:721-722.
1. Schurr R SU, Schuppan D . Increased incidence of hepatocellular and intrahepatic cholangiocellular carcinoma in northeast Germany. Dtsch Med Wochenschr 2006;131:7.
2.朱明华.肝脏肿瘤病理学展望.中华病理学杂志2007;36:721-722.
3.杨红梅.“晕圈”在超声诊断原发性肝癌中的价值.中国基层医药2006;13:1639-1640.
4.周永昌,郭万学.超声医学.北京:科学技术文献出版社, 2003.
5. Kadoya MD MM, Takashirna MD. Hepa-tocellular carcinoma: Correlation of M R imaging and histopathologic findings. Radiology 1992;183:819.
6.董敬东(综述),王莉芬(审校).原发性肝癌影像学特征与病理学关系的研究进展.大连医科大学学报2005:474-476.
7. Itoh Y AK. Relationship between echo level and histologic characteristics in small hepatocellular carcinomas. Clin Ultrasound 1998;26:295-301.
8.王知力,董宝玮,梁萍,于晓玲,于德江,张晶.肝细胞肝癌灰阶超声强度与其组织病理相关性的研究.中国超声医学杂志2004:602-605.
9. Davis PL, Filly RA, Goerke J. In vitro demonstration of an echogenic emulsion: relationship of lipid particle size to echo detection. J Clin Ultrasound 1981;9:263-266.
10. Kenmochi K SS, Kojiro M. Relationship of histologic grade of hepatoceIluIar carcioma(HCC)to tumor size,and demonstration of tumor cells of multiple different grades in single small HCC. Liver 1987;7:18-26.
11. Sugihara S NO, Kojiro M . The morphologic transition in hepatoceIlular carcinoma. Cancer Control 1992;15:1488-1492.
12.李瑞珍,何炜.小肝癌的超声多普勒显像与病理分级相关性的研究.医学临床研究2004 21:214-217.
13. Bude RO RJ, Adler RS. Power versus conventional color Doppler sonography : comparison in the depiction of normal intrarenal vasculature. Radiology 1994;192:777-780.
14. Koito K, Namieno T, Morita K. Differential diagnosis of small hepatocellular carcinoma and adenomatous hyperplasia with power Doppler sonography. Ajr 1998;170:157-161.
15. Imamura H, Matsuyama Y, Tanaka E, Ohkubo T, Hasegawa K, Miyagawa S, . Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. Journal of hepatology 2003;38:200-207.
16. Yamamoto T, Hirohashi K, Kaneda K, Ikebe T, Mikami S, Uenishi T . Relationship of the microvascular type to the tumor size, arterialization and dedifferentiation of human hepatocellular carcinoma. Jpn J Cancer Res 2001;92:1207-1213.
17. Sato S, Shiratori Y, Imamura M, Obi S, Shiina S, Akahane M . Re-appearance of power Doppler signals in the tumor nodules of hepatocellular carcinoma after transarterial embolization reflects residual viable tumor cells: histological confirmation. Hepato-gastroenterology 2004;51:56-61.
18. Battula N, Madanur M, Priest O, Srinivasan P, O'Grady J, Heneghan MA . Spontaneous rupture of hepatocellular carcinoma: a Western experience. American journal of surgery 2009;197:164-167.
19. Al-Mashat FM, Sibiany AM, Kashgari RH, Maimani AA, Al-Radi AO, Balawy IA . Spontaneous rupture of hepatocellular carcinoma. Saudi medical journal 2002;23:866-870.
20. Zhu LX, Wang GS, Fan ST. Spontaneous rupture of hepatocellular carcinoma. The British journal of surgery 1996;83:602-607.
21. Zhu LX, Geng XP, Fan SD. Ultrastructure study on patients with spontaneous rupture of hepatocellular carcinoma. Zhonghua wai ke za zhi [Chinese journal of surgery] 2006;44:161-164.
22.高秀荣,迟玉花.肝癌自发性破裂出血的超声显像诊断.中国超声医学杂志1997:69-70.
23. Lai EC, Lau WY. Spontaneous rupture of hepatocellular carcinoma: a systematic review. Arch Surg 2006;141:191-198.
24. Minagawa M, Makuuchi M, Takayama T, Ohtomo K. Selection criteria for hepatectomy in patients with hepatocellular carcinoma and portal vein tumor thrombus. Annals of surgery 2001;233:379-384.
25.杨维秀,陈汉荣.彩色多普勒血流显像对血管内血栓和瘤栓的鉴别诊断.同济医科大学学报1997:401-402,408.
26. Ricci P, Cantisani V, Biancari F, Drud FM, Coniglio M, Di Filippo A . Contrast-enhanced color Doppler US in malignant portal vein thrombosis. Acta Radiol 2000;41:470-473.
27. Ueno N, Kawamura H, Takahashi H, Fujisawa N, Yoneda M, Kirikoshi H . Characterization of portal vein thrombus with the use of contrast-enhanced sonography. J Ultrasound Med 2006;25:1147-1152.
28. Tarantino L, Francica G, Sordelli I, Esposito F, Giorgio A, Sorrentino P. Diagnosis of benign and malignant portal vein thrombosis in cirrhotic patients with hepatocellular carcinoma: color Doppler US, contrast-enhanced US, and fine-needle biopsy. Abdominal imaging 2006;31:537-544.
29. Tola M, Yurdakul M, Okten S, Ozdemir E, Cumhur T. Diagnosis of arterial occlusive disease of the upper extremities: comparison of color duplex sonography and angiography. J Clin Ultrasound 2003;31:407-411.
30.罗淑荣,段云友,等.彩超诊断门脉癌栓.中国医学影像技术2002:59-60.
31. Zech CJ, Schoenberg SO, Reiser M, Helmberger T. Cross-sectional imaging of biliary tumors: current clinical status and future developments. European radiology 2004;14:1174-1187.
32. Hung MC, Wu HS, Lee YT, Hsu CH, Chou DA, Huang MH. Intraperitoneal metastasis ofhepatocellular carcinoma after spontaneous rupture: a case report. World J Gastroenterol 2008;14:3927-3931.
33.郭春苗,王静意. B超在以胆管癌栓为主要征象的肝癌中的诊断价值.临床医学1996:6-7.
1. Eguchi S, Kanematsu T, Arii S, Okazaki M, Okita K, Omata M, . Comparison of the outcomes between an anatomical subsegmentectomy and a non-anatomical minor hepatectomy for single hepatocellular carcinomas based on a Japanese nationwide survey. Surgery 2008;143:469-475.
2. Livraghi T. Radiofrequency ablation, PEIT, and TACE for hepatocellular carcinoma. Journal of hepato-biliary-pancreatic surgery 2003;10:67-76.
3.杨健,杨超.原发性肝癌术后复发的再治疗.江西医药2008:300-302.
4.周永昌,郭万学.超声医学.北京:科学技术文献出版社, 2003.
5.李波,吴孟超.术后复发性肝癌瘤内酒精注射治疗.中华肿瘤杂志1995:371-373.
6. Koike Y, Shiratori Y, Sato S, Obi S, Teratani T, Imamura M, . Des-gamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients. Cancer 2001;91:561-569.
7. Teratani T, Ishikawa T, Shiratori Y, Shiina S, Yoshida H, Imamura M, . Hepatocellular carcinoma in elderly patients: beneficial therapeutic efficacy using percutaneous ethanol injection therapy. Cancer 2002;95:816-823.
8. Seki T, Nonaka T, Kubota Y, Mizuno T, Sameshima Y. Ultrasonically guided percutaneous ethanol injection therapy for hepatocellular carcinoma. The American journal of gastroenterology 1989;84:1400-1407.
9. Lin LW, Lin XY, He YM, Gao SD, Lin XD. Biological characteristics of HCC by ultrasound-guided aspiration biopsy and its clinical application. World J Gastroenterol 2003;9:941-945.
10. Rustemovic N, Vucelic B, Opacic M, Ostojic R, Pulanic R, Petrovecki M, . Palliative treatment of hepatocellular carcinoma with percutaneous ethanol injection using tumor's feeding artery occlusion under the ultrasonic color Doppler guidance. Collegium antropologicum 2004;28:781-791.
11.杨嘉嘉(综述),林礼务(审校).超声介入注射无水乙醇治疗肝癌的研究现状及进展.中国医学影像技术2008:293-296.
12. Nishiharu T, Maeda N, Hara M, Yamashita Y. [Usefulness of enhanced ultrasonography after administration of intravenous contrast agent in the evaluation of therapeutic effect in treatment of hepatocellular carcinoma, and efficacy of percutaneous ethanol injection therapy (PEIT) for residual tumor]. Nihon Igaku Hoshasen Gakkai zasshi 2001;61:790-795.
13. Numata K, Isozaki T, Ozawa Y, Sakaguchi T, Kiba T, Kubota T, . Percutaneous ablation therapy guided by contrast-enhanced sonography for patients with hepatocellular carcinoma. Ajr 2003;180:143-149.
14. Ho CS, Kachura JR, Gallinger S, Grant D, Greig P, McGilvray I, . Percutaneous ethanol injection of unresectable medium-to-large-sized hepatomas using a multipronged needle: efficacy and safety. Cardiovascular and interventional radiology 2007;30:241-247.
15. Tanikawa K, Majima Y. Percutaneous ethanol injection therapy for recurrent hepatocellular carcinoma. Hepato-gastroenterology 1993;40:324-327.
16. Shiratori Y, Shiina S, Teratani T, Imamura M, Obi S, Sato S, . Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Annals of internal medicine 2003;138:299-306.
17. Ferlitsch A, Kreil A, Bauer E, Schmidinger H, Schillinger M, Gangl A, . Bradycardia and sinus arrest during percutaneous ethanol injection therapy for hepatocellular carcinoma. European journal of clinical investigation 2004;34:218-223.
18. Noda T, Nagano H, Murakami M, Kobayashi S, Marubashi S, Miyamoto A, . [Surgical treatment for peritoneal seeding and needle-tract implantation of hepatocellular carcinoma after ultrasound-guided percutaneous puncture]. Gan to kagaku ryoho 2007;34:2080-2083.
19. Chan RP, Asch M, Kachura J, Ho CS, Greig P, Langer B, . Radiofrequency ablation of malignant hepatic neoplasms. Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes 2002;53:272-278.
20. Lencioni R, Crocetti L. Radiofrequency ablation of liver cancer. Techniques in vascular and interventional radiology 2007;10:38-46.
21.杜锡林,马庆久,褚延魁,高德明,杨媛,臧莉,等.射频消融(Rfa)治疗肝癌的临床研究.肝胆外科杂志2008:260-262.
22.王妍(综述),任正刚(审校).射频治疗肝癌术后复发的相关因素.中国肿瘤临床2008:411-414.
23. Kondo Y, Yoshida H, Tateishi R, Shiina S, Kawabe T, Omata M. Percutaneous radiofrequency ablation of liver cancer in the hepatic dome using the intrapleural fluid infusion technique. The British journal of surgery 2008;95:996-1004.
24. Weinberg BD, Blanco E, Lempka SF, Anderson JM, Exner AA, Gao J. Combined radiofrequency ablation and doxorubicin-eluting polymer implants for liver cancer treatment. Journal of biomedical materials research 2007;81:205-213.
25. Helton WS. Minimizing complications with radiofrequency ablation for liver cancer: the importance of properly controlled clinical trials and standardized reporting. Annals of surgery 2004;239:459-463.
26. Ma K, Min C, Ian HX, Jiahong D. Prevention and cure of complications from multiple-electrode radiofrequency treatment of liver tumors. Digestive diseases (Basel, Switzerland)2001;19:364-366.
27. Tsui SL, Lee AK, Lui SK, Poon RT, Fan ST. Acute intraoperative hemolysis and hemoglobinuria during radiofrequency ablation of hepatocellular carcinoma. Hepato-gastroenterology 2003;50:526-529.
28. Meloni MF, Goldberg SN, Moser V, Piazza G, Livraghi T. Colonic perforation and abscess following radiofrequency ablation treatment of hepatoma. Eur J Ultrasound 2002;15:73-76.
29.夏景林,任正刚,叶胜龙,干育红,王艳红,张博恒.肝癌射频消融治疗严重或少见并发症分析.中国微创外科杂志2005:268-270.
30. Jaskolka JD, Asch MR, Kachura JR, Ho CS, Ossip M, Wong F . Needle tract seeding after radiofrequency ablation of hepatic tumors. J Vasc Interv Radiol 2005;16:485-491.
31.刘元水,郑晓寰.原发性肝癌的冷冻消融治疗.山东医药2008;48:102-103.
32. Hinshaw JL, Lee FT, Jr. Cryoablation for liver cancer. Techniques in vascular and interventional radiology 2007;10:47-57.
33. Hu KW, Li QW, Zuo MH, Sun T, Jiang M. Clinical observation on the combined treatment of
57 cases of non-small cell lung cancer using argon-helium cryosurgery and Chinese herbal medicine. Chinese journal of integrative medicine 2007;13:224-227.
34.胡士杰,吴健雄,荣维淇,祁付珍,朱怀宇.经皮微波凝固治疗肝癌的研究进展.中国肿瘤临床与康复2005;12:471-472.
35. Heisterkamp J, van Hillegersberg R, Ijzermans JN. Interstitial laser coagulation for hepatic tumours. The British journal of surgery 1999;86:293-304.
36. Goldberg SN. Comparison of techniques for image-guided ablation of focal liver tumors. Radiology 2002;223:304-307.
37. Shibata T, Morita T, Okuyama M, Kitada M, Tsukahara Y, Ikeda K . Comparison of microwave coagulation using a new type electrode with radiofrequency ablation in the liver of living animals. Gan to kagaku ryoho 2001;28:1595-1598.
38. Satoi S, Kamiyama Y, Matsui Y, Kitade H, Kaibori M, Yamamoto H. Clinical outcome of 214 liver resections using microwave tissue coagulation. Hepato-gastroenterology 2005;52:1180-1185.
39. Aramaki M, Kawano K, Ohno T, Sasaki A, Tahara K, Kai S. Microwave coagulation therapy for unresectable hepatocellular carcinoma. Hepato-gastroenterology 2004;51:1784-1787.
40.李东方,宋晓红,梁晓玲,邢超,张蓉蓉.腹壁烫伤——肝癌微波凝固治疗中不可忽视的并发症.中华肝胆外科杂志2006;12:392-392.
41.张丽,郭佳.原发性肝癌超声特性和组织病理学分型相关性分析.中国超声医学杂志2009;25:149-151.
42. Watanabe Y, Sato M, Abe Y, Horiuchi S, Kito K, Kimura K . Laparoscopic microwave coagulo-necrotic therapy for hepatocellular carcinoma: a feasible study of an alternative option for poor-risk patients. Journal of laparoendoscopic surgery 1995;5:169-175.
43. Yamakado K, Nakatsuka A, Takaki H, Mori Y, Tonouchi H, Kusunoki M . Prospective study of arterial infusion chemotherapy followed by radiofrequency ablation for the treatment of liver metastasis of gastric cancer. J Vasc Interv Radiol 2005;16:1747-1751.
44. Lin LW, Sun Y, He YM, Gao SD, Xue ES, Lin XD. Percutaneous intratumoral injection of traditional Chinese herbal compound medicine Star-99 in treatment of hepatocellular carcinoma of mice. Hepatobiliary Pancreat Dis Int 2004;3:49-54.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |